Basic Information
| LncRNA/CircRNA Name | LINC01234 |
| Synonyms | NA |
| Region | GRCh38_12:113679459-113773683 |
| Ensemble | ENSG00000249550 |
| Refseq | NR_110026 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, Luciferase reporter assay etc. |
| Sample | NSCLC tumors compared with adjacent normal tissues, cell lines (A549, SPC-A1, PC9, H1299, H1975, H226 and H1703) |
| Expression Pattern | up-regulated |
| Function Description | LINC01234 Is Highly Expressed in NSCLC and Correlates withPoor Prognosis. Accordingly, depletion of either LINC01234 or HNRNPA2B1 reduced the processing of several miRNA precursors, including primary microRNA (pri-miR)-106b. miR-106b-5p enhanced NSCLC cell growth by downregulating cryptochrome 2 (CRY2), thereby increasing c-Myc expression. Finally, we found that activated c-Myc binds to the LINC01234 promoter to increase its transcription, creating a c-Myc-LINC01234-HNRNPA2B1-miR-106b-5p-CRY2-c-Myc positive-feedback loop. |
| Pubmed ID | 32246902 |
| Year | 2020 |
| Title | Integrative Analysis of NSCLC Identifies LINC01234 as an Oncogenic lncRNA That Interacts With HNRNPA2B1 and Regulates miR-106b Biogenesis |
External Links
| Links for LINC01234 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |